Elevation Oncology, Inc.
ELEV · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $7 | $7 | $9 | $7 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $11 | $13 | $11 |
| Operating Income | -$14 | -$11 | -$13 | -$11 |
| % Margin | – | -28,005.3% | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$14 | -$10 | -$13 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$10 | -$13 | -$10 |
| % Margin | – | -27,463.2% | – | – |
| EPS | -0.24 | -0.18 | -0.22 | -0.18 |
| % Growth | -33.3% | 18.2% | -22.2% | – |
| EPS Diluted | -0.24 | -0.18 | -0.22 | -0.18 |
| Weighted Avg Shares Out | 59 | 59 | 59 | 59 |
| Weighted Avg Shares Out Dil | 59 | 59 | 59 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$9 | -$13 | -$11 |
| % Margin | – | -24,905.3% | – | – |